subject
re
sterling
stock
watch
smallcap
biotech
report
stem
cell
cryogenics
stem
cell
investing
emerging
biotech
stocks
company
spotlight
bio
matrix
scientific
group
inc
driving
75
billion
dollar
year
biotechnology
medical
device
industries
demand
new
products
improve
patient
safety
decrease
healthcare
cost
importantly
enhance
human
life
symbol
bmxp
trading
price
0
94
bio
matrix
scientific
group
inc
bio
matrix
scientific
group
inc
san
diego
based
development
stage
company
business
medical
devices
monitoring
systems
research
development
commercialization
bio
matrix
scientific
group
inc
aligning
itself
partners
offer
key
technologies
biomedical
device
development
tissue
engineering
cell
culturing
genome
therapy
drug
delivery
systems
polymer
coating
medical
devices
ensure
cell
transference
done
minimal
damage
cells
lead
better
yields
stem
cell
extraction
along
better
outcomes
patients
tissue
management
procedures
recent
news
spokesperson
company
board
directors
plans
spin
6
035
501
shares
common
stock
frezer
inc
wholly
owned
subsidiary
bio
matrix
scientific
group
bmxp
shareholders
record
31
2005
represents
one
share
frezer
inc
one
share
bio
matrix
scientific
group
inc
pink
sheets
bmxp
owned
post
reverse
split
ground
floor
company
enters
production
phase
bio
matrix
scientific
group
inc
announced
collective
technologies
manufacture
bio
matrix
first
set
stem
cell
devices
company
anticipates
having
set
instruments
sometime
within
next
two
weeks
bmxp
recently
finalized
applications
3
new
devices
first
step
towards
full
production
devices
first
set
devices
used
510
k
testing
trade
shows
presentations
physicians
researchers
collective
technologies
enables
manufacture
products
efficient
cost
effective
way
possible
noted
brian
pockett
managing
director
coo
bio
matrix
scientific
impressed
collective
technologies
quality
record
responsiveness
flexibility
critical
production
objectives
bio
matrix
sees
event
nearing
point
company
green
lights
full
production
stem
cell
tissue
management
instruments
real
deal
management
philip
watts
ph
d
company
director
research
development
highly
recognized
field
james
l
lambert
ph
d
bio
instrument
scientific
advisor
dr
lambert
specializes
development
next
generation
bio
instrumentation
use
medical
research
dr
lambert
jet
propulsion
laboratory
17
years
last
five
years
served
technical
group
supervisor
intelligent
instrument
systems
technology
group
dr
lambert
leads
multidisciplinary
group
whose
members
advanced
degrees
chemistry
biology
electrical
engineering
computer
science
charter
group
develop
advanced
situ
instruments
sensors
nasa
agencies
geoffrey
o
neill
ph
d
president
company
dr
o
neill
recently
served
director
stem
cell
laboratories
scientific
research
cryo
cell
international
inc
otc
ccel
cryo
cell
international
represents
themselves
world
largest
u
cord
stem
cell
banking
firm
appointment
dr
o
neill
president
bio
matrix
scientific
group
inc
signals
company
aggressive
growth
plans
stem
cell
research
devices
biomedical
devices
continued
growth
development
stem
cell
cryogenic
banks
brian
pockett
managing
director
coo
bio
matrix
scientific
product
development
stem
cell
cryogenics
instrumentation
stem
cell
research
tissue
management
non
invasive
bio
systems
monitoring
measuring
devices
niche
medical
device
instrumentation
company
recently
filed
provisional
patent
application
u
patent
office
anticipates
numerous
utility
patents
result
filing
investment
prosective
bio
matrix
four
pronged
revenue
strategy
each
different
trajectory
different
inflection
points
company
spreading
risk
over
different
operating
segments
varying
investment
requirement
levels
risk
larger
companies
medical
device
industry
aggressive
smaller
companies
always
takeover
targets
potential
bmxp
market
size
segments
chosen
operate
huge
tissue
management
instruments
market
size
alone
860
million
provisional
patent
application
already
filed
more
pipeline
important
disclaimer
information
within
email
contains
forward
looking
statements
within
meaning
section
27
securities
act
1933
section
21
b
securities
exchange
act
1934
statements
express
involve
discussions
respect
predictions
goals
expectations
beliefs
plans
projections
objectives
assumptions
future
events
performance
statements
historical
fact
forward
looking
statements
forward
looking
statements
based
expectations
estimates
projections
time
statements
made
involve
number
risks
uncertainties
cause
actual
results
events
differ
materially
those
presently
anticipated
forward
looking
statements
action
identified
through
use
words
projects
foresee
expects
estimates
believes
understands
anticipates
statements
indicating
certain
actions
occur
information
provided
within
email
pertaining
investing
stocks
securities
understood
information
provided
investment
advice
emerging
equity
alert
advises
readers
subscribers
seek
advice
registered
professional
securities
representative
before
deciding
trade
stocks
featured
within
email
none
material
within
report
shall
construed
kind
investment
advice
compliance
section
1
compensated
thirty
thousand
dollars
dissemination
profile
aware
inherent
conflict
interest
resulting
holdings
due
intent
profit
liquidation
shares
shares
sold
time
even
positive
statements
made
regarding
above
company
